Base editing marches on the clinic
By Michael Eisenstein,
Nature
| 05. 09. 2022
This year could see the first trials of therapies employing base editing that introduce precise single-nucleotide changes into patient genomes.
Two companies, Beam Therapeutics and Verve Therapeutics, are leading the charge of base editing therapies to the clinic. Last November, Beam got the green light from the US Food and Drug Administration (FDA) for its upcoming BEACON-101 trial that will use base editing to restore expression of fetal globin in bone marrow stem cells. In parallel, Verve is preparing to embark on an in vivo base editing trial to treat patients who have experienced a heart attack and have abnormally high cholesterol levels by targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene, after obtaining promising results from preclinical work in rodents and non-human primates. “We’re optimistic about dosing our first patients in the second half of this year,” says Verve CEO and co-founder Sekar Kathiresan. The rapid progress of base editing programs is attracting interest from major pharmaceutical companies: in January, Beam entered a collaboration with Pfizer that could net the company up to $1.3 billion.
Beam’s rapid progress to the clinic — using technology developed just six years ago — has been built on the shoulders...
Related Articles
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...
By Daniel Gilbert, The Washington Post | 03.07.2024
Vitaly Kushnir’s fertility clinic offers to screen an embryo to predict a baby’s sex, but the service can lead to ethically murky territory, like when a couple wanted it so their first child could be a boy.
But the couple...
By Manuel Ansede, El País | 03.01.2024
A team of Italian researchers has reached a major scientific milestone, heralding a revolution in the field of medicine. The scientists have succeeded in silencing a gene associated with high cholesterol levels, without the need to modify DNA. In the...